Overview

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.
Phase:
Phase 2
Details
Lead Sponsor:
Palak Shah, MD
Collaborator:
Abbott Medical Devices
Treatments:
Apixaban
Warfarin